News Search & Analytics
US Edition
Minimum 3 characters required!!
Report Based On Past 7 Days Data
2
Total Articles
2
Total Publisher Covering articles
1
Highest On 2017-05-24
0
Articles Got Popular On Social Media
gilead sciences found in Articles in last 7 Days

Top Articles

Oct 20 Gilead Sciences Inc : * Gilead announces top-line phase 2 results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and...
Oct 20 Gilead Sciences Inc * Gilead announces SVR12 rates from four phase 3 studies of a once-daily, fixed-dose combination of Sofosbuvir, Velpatasvir and Voxilaprevir in treatment...
Sept 27 Gilead Sciences * Gilead Sciences and the World Health Organization announce five-year visceral leishmaniasis collaboration * Partnership with World Health Organization to ...
Oct 20 (Reuters) - Gilead Sciences Inc : * Gilead announces top-line phase 2 results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertensi...
Nov 16 Gilead Sciences Inc : * Gilead Sciences Inc - non-inferiority was not achieved for key secondary endpoint of response rate in total symptom score (TSS) * Gilead announces to...
BRIEF-Gilead presents new phase 2 data on Bictegravir
-Reuters - Mon Feb 13 14:05:30 EST 2017
Feb 13 Gilead Sciences Inc : * Gilead presents new phase 2 data on Bictegravir, an investigational integrase strand transfer inhibitor for the treatment of HIV * Bictegravir in com...
July 22 Gilead Sciences Inc * European CHMP adopts positive opinion on Gilead's type II variation application for Truvada for reducing the risk of --- acquired HIV. * CHMP's ...
Obama on Turkish Coup, Fethullah Gülen, Erdogan Crackdown
-Investing - Mon Jul 25 17:10:22 EDT 2016
Shares in Gilead Sciences plunge 3% amid disappointing Harvoni sales Investing.com -- Shares in Gilead Sciences Inc (NASDAQ:GILD) fell sharply in after-hours trading after sales in...
June 23 Gilead Sciences Inc * European Commission grants marketing authorization for Gilead's single tablet regimen Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) for...
Aug 10 Genmab A/S : * Genmab enters commercial license agreement with Gilead for DuoBody(R) Technology * Genmab is entitled to potential development, regulatory and sales milestone...
Why Gilead Sciences Shares Fell 7% in October | Fox Business
-Fox Business - Tue Nov 08 13:53:26 EST 2016
Image source: Getty Images. Worries that hepatitis C sales will remain a headwind to top- and bottom-line growth caused Gilead Sciences (NASDAQ: GILD) shares to decline 7% in Octob...
Image source: Gilead Sciences, Inc. While following blindly in the footsteps of billionaires is risky, it's always interesting to see what stocks legendary investing gurus are sell...
U.S. FDA approves Gilead's hep C drug Epclusa
-Reuters - Tue Jun 28 08:16:38 EDT 2016
June 28 The U.S. Food and Drug Administration approved Gilead Sciences Inc's drug for treating chronic hepatitis C virus infection. The drug, Epclusa, is approved for use in combin...
BRIEF-Gilead Sciences prices $5 bln of senior unsecured notes
-Reuters - Thu Sep 15 20:14:16 EDT 2016
Sept 15 Gilead Sciences Inc : * Gilead prices $5 billion of senior unsecured notes * Priced $1.25 billion of 2.950% senior notes maturing in 2027 * Priced $750 million of 2.500% se...
After Rough Patch,Gilead Shouldn't Succumb to Deal Pressure
-The Wall Street Journal - Sun Nov 20 11:00:57 EST 2016
Gilead Sciences shareholders have faced unrelenting disappointment lately. The rough ride isn’t a reason to abruptly change its deal strategy, though. The latest blow: Gilead annou...
Gilead's Boom Fades and --- Will Linger
-The Wall Street Journal - Wed Feb 08 07:14:15 EST 2017
Gilead Sciences, perhaps the company most responsible for powering the last biotech bull market, has a revenue problem on its hands. Its struggles highlight how quickly the moment ...
Gilead Goes to the Head of the Line
-The Wall Street Journal - Tue Feb 21 10:11:23 EST 2017
A lack of deal activity at Gilead Sciences Inc. has lately frustrated shareholders. But company executives know a bargain when they see one. The biotech giant purchased a priority ...
EU regulators recommend approving Gilead's new hepatitis C drug
-Reuters - Fri May 27 08:14:34 EDT 2016
Gilead Sciences Inc's new hepatitis C drug combination, which shares an active ingredient with blockbuster Sovaldi, was recommended for marketing approval by the European Medicines...
Why You're Right to Invest in Gilead Sciences Stock | Fox Business
-Fox Business - Mon Jan 30 10:04:15 EST 2017
With the Dow Jones Industrial Average blasting through the 20,000 mark, many stocks are currently trading at or near their all-time highs. Unfortunately, biotechnology investors ha...
3 Reasons Gilead Sciences Is a Buy | Fox Business
-Fox Business - Fri Jun 17 14:05:24 EDT 2016
Drugmaking giant Gilead Sciences has fallen out of favor with investors because sales of its hepatitis C drugs are flat-lining, but shunning Gilead Sciences may not be best long-te...
Image source: Gilead Sciences. The Americans for Tax Fairness has sent a request to the Internal Revenue Service to launch an investigation into whetherGilead Sciences (NASDAQ: GIL...
Investors have turned to the pharmaceutical industry for solid dividend stocks for a long time. However, biotechs typically weren't high on the list when it came to dividends. Over...
The Pros and Cons of Buying Gilead Sciences Stock | Fox Business
-Fox Business - Thu Sep 22 08:04:46 EDT 2016
Image source: Stockmonkeys.com via Flickr. Gilead Sciences (NASDAQ: GILD) is a biotech Goliath generating $30 billion in annualized sales and $14 billion in annualized net income. ...
Gilead Sciences Inc. makes the two leading drugs that can quickly cure hepatitis C infections. But most patients can't afford the expensive drugs, and states restrict their use amo...
Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district judge has ruled...
(Reuters) - Gilead Sciences Inc is entitled to receive the attorney fees it incurred related to hepatitis C patent litigation with drugmaker Merck & Co Inc, a U.S. district jud...
Image source: Ionis Pharmaceuticals, Inc. A spat between Merck & Co. and Gilead Sciences that could have a big impact on Ionis Pharmaceuticals, Inc. has taken a turn for the wo...
Gilead Sciences names Kevin Young as new Chief Operating Officer
-Investing - Tue May 24 17:11:13 EDT 2016
Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) announced a host of changes to its executive management structure on Tuesday, including the appointment of Kevin Young as the com...
Shares of Gilead Sciences Inc. declined in Monday's extended session after the biopharmaceutical company lowered its 2016 outlook on product sales despite turning in better-than-ex...
Gilead poaches Novartis cancer specialist Riva
-Reuters - Wed Jan 04 01:27:39 EST 2017
ZURICH Gilead Sciences has hired a top cancer specialist from Swiss drugmaker Novartis as the U.S. healthcare group sharpens its focus on oncology. Alessandro Riva will become a Gi...
Advertisement
Publishers
Number of articles

1

1